论文部分内容阅读
【目的】探讨氨磺必利治疗精神分裂症的临床疗效与安全性。【方法】121例精神分裂症患者随机分为氨磺必利组（N＝61）与奥氮平组（N＝60）两组，分别予以氨磺必利与奥氮平治疗，疗程12周。采用阳性和阴性症状量表（PANSS）、副反应量表（TESS）评定疗效和不良反应。【结果】治疗12周后，氨磺必利组的有效率为83．6％，奥氮平组的有效率为86．7％，两组的差异无统计学意义（ P ＞0．05）；氨磺必利组与奥氮平组患者PANSS总分治疗后（41．79±9．66，46．56±9．88）均较治疗前（91．76±13．06，94．83±15．67）有显著下降（ P ＜0．01）；氨磺必利组患者在治疗12周后 PANSS阴性症状分值为（9．61±3．86）分，降低较奥氮平组（12．56±6．15）更为显著（ P ＜0．05）。两组不良反应发生率的差异无统计学意义（ P ＞0．05）。【结论】氨磺必利与奥氮平总体疗效相似，对阴性症状改善较好，不良反应轻，安全性高。“,”[Objective]To explore clinical efficacy and safety of amisulpride in the treatment of schizophre-nia .[Methods] Totally 121 patients with schizophrenia were randomly assigned to amisulpride group ( n=61) and olanzapine group( n=60) .Two groups were treated with amisulpride and olanzapine respectively for 12 weeks .The efficacy and side reactions were evaluated with positive and negative syndrome scale (PANSS) and treatment emergent symptom scale (TESS ) .[Results] After 12 weeks of treatment , the effective rate of amisulpride and olanzapine were 83 .6% and 86 .7% respectively ,but there was no significant difference be-tween two groups( P > 0 .05) .Compared with before treatment ,the total scores of PANSS in amisulpride group and olanzapine group after treatment were significantly decreased [(41 .79 ± 9 .66) vs .(91 .76 ± 13 .06) , (46 .56 ± 9 .88) vs .(94 .83 ± 15 .67)]( P <0 .01) .The negative symptom scores of PANSS in amisulpride group after 12 weeks of treatment were decreased more significant than those in olanzapine group [(9 .61 ± 3 .86) vs .(12 .56 ± 6 .15)]( P 0 .05) .[Conclusion]The total efficacy of amisulpride is similar to olanzapine ,. Amisulpride can better improve negative symptoms ,and has mild side reaction and high safety .